BioInvent International
4.11.2021 14:27:04 CET | ACCESS Newswire | Press release
- BI-1206 restores rituximab activity in relapsed or refractory patients
- Demonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 months
LUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206. The data update comes from the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The latest data will be published in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) in December 2021.
BI-1206 in combination with rituximab demonstrated an objective response rate (ORR) of 50%, with three complete responses and three partial responses seen in twelve patients evaluated for therapeutic benefit. The treatment stabilized disease in one additional patient, giving a disease control rate of 58% (7 out of 12 patients). The complete responses also appear to be long-lasting, sustaining beyond 18 months and beyond 24 months in two patients completing the study. Previous rituximab treatments without BI-1206 had failed in these patients. The data were obtained from the dose-escalation phase of the trial up to July 2021 (the ASH abstract cut-off date). BI-1206 showed a good safety profile: infusion-related reactions can be managed with a steroid regimen.
"The current data are very encouraging and already show the benefit of BI-1206 in advanced NHL. Without BI-1206, single agent rituximab does not work well for this group of patients. These results suggest that BI-1206 not only restores the anti-tumor response but can do it in a prolonged manner in many patients. All this has been achieved with a dosing regimen for BI-1206 that may yet be further improved, and we look forward to continuing its clinical development with the aim of improving treatment options for these patients," said Martin Welschof, PhD, CEO of BioInvent.
Pharmacodynamic studies highlighted in the ASH 2021 abstract suggest that increasing the dosing of BI-1206 could lead to complete receptor saturation over an extended time, potentially leading to additional clinical benefits.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent will present a poster entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcγRIIB (CD32B), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The abstract is available online from November 4, 2021, at 9.00 am EDT (2 pm CET) and will be presented on December 11 at 5.30 pm ET (11:30 pm CET).
In mid-December, BioInvent will hold a live-streamed KOL event where the ASH poster data will be discussed. In addition, the first data from the Phase 1/2a study of BI-1206 in combination with Keytruda for the treatment of solid tumors will be reviewed.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-04 14:00 CET.
Attachments
BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
SOURCE: BioInvent International AB
View source version on accesswire.com:
https://www.accesswire.com/671193/BioInvent-to-Show-Further-Positive-BI-1206-Clinical-Data-in-December-at-ASH-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ore Energy Raises $43 Million to Unlock Renewable Baseload Power for the AI Era4.8.2026 09:00:00 CEST | Press release
Ore Energy is building a fully European-manufactured battery to solve one of the biggest bottlenecks in the energy transition: multi-day storage Europe already wastes an estimated 72 TWh of renewable energy due to grid bottlenecks, equivalent to Austria's annual electricity demand, with losses projected to rise to as much as 410 TWh annually by 2040, according to the European Commission's Joint Research Centre Its iron-air batteries store power for 100 hours at 10x lower cost per unit of energy capacity than lithium-ion, without the need for critical raw minerals like lithium or cobalt AMSTERDAM, NL AND DELFT, NL / ACCESS Newswire / August 4, 2026 / As demand for electricity from AI, manufacturing, and the energy transition accelerates worldwide, Ore Energy has raised $43 million in Series A funding from Plural and HV to scale its iron-air battery technology. Ore's batteries, designed to store renewable electricity for up to 100 hours, can solve one of the biggest barriers to the energ
Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination1.8.2026 01:15:00 CEST | Press release
Strategic Transaction to Position Thunder Bay North for Development, Strengthen Capital Markets Profile and Create a New Critical Minerals Growth Platform Not for distribution to United States newswire services or for dissemination in the United States. Highlights A strategic business combination with Springbok Ventures, a Fiore Group-backed company focused on critical minerals in Ontario Creation of a growth-oriented critical minerals platform focused on domestic critical minerals in Canada with the ability to pursue future acquisitions and strategic opportunities Minimum C$5 million concurrent financing of subscription receipts Partnership with the Fiore Group, one of Canada's leading mining groups Continued advancement of the Thunder Bay North Critical Minerals Project Addition of the Maude Lake Property in Ontario as an exploration asset THUNDER BAY, ON / ACCESS Newswire / July 31, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF), 1602037 B.C. Ltd.
Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested30.7.2026 21:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 30, 2026 / A new scientific review has found that nutritionally sound vegan dog food, vegan cat food and vegetarian pet diets are generally well digested and broadly comparable to conventional meat-based diets. The review, published in the journal Animals, examined 31 existing studies assessing the digestibility of vegan, vegetarian and plant-based pet diets and ingredients in dogs and cats. Twenty-two studies focused on dogs, two on cats and seven included both species. The review found that across a wide range of study designs, dietary ingredients and digestibility measures, vegan and vegetarian diets consistently showed high digestibility and were not normally significantly less digestible than conventional meat-based diets. Digestibility is an important factor because it indicates how effectively animals can absorb and utilise nutrients from food. While modern commercial plant-based pet foods are generally formulated to provide all essential nutr
Polaris Renewable Energy Announces Q2 2026 Results30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS Second quarter consolidated energy production totaled 199,130 MWh, representing a 8% decrease from 215,797 MWh in the same quarter last year. The decrease was consistent with management's expectations and primarily reflects higher curtailment in the Dominican Republic and the return to normalized hydrological conditions in Peru and Ecuador. The comparative period benefited from exceptionally strong
Polaris Renewable Energy Declares Quarterly Dividend30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 21st, 2026, to shareholders of record at the close of business on August 10th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom